86 related articles for article (PubMed ID: 24197988)
1. Comprehensive analysis reveals that LTBR is a immune-related biomarker for glioma.
Tang Q; Yuan Y; Li L; Xu Y; Ji W; Xiao S; Han Y; Miao W; Cai J; You P; Chen M; Ding S; Li Z; Qi Z; Hou W; Luo H
Comput Biol Med; 2024 May; 174():108457. PubMed ID: 38599071
[TBL] [Abstract][Full Text] [Related]
2. Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.
Chen R; Nishimura MC; Kharbanda S; Peale F; Deng Y; Daemen A; Forrest WF; Kwong M; Hedehus M; Hatzivassiliou G; Friedman LS; Phillips HS
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14217-22. PubMed ID: 25225364
[TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibitors for cancer immunotherapy and associated biomarkers - the current status.
Schlicher L; Green LG; Romagnani A; Renner F
Front Immunol; 2023; 14():1297175. PubMed ID: 38022587
[TBL] [Abstract][Full Text] [Related]
4. Liquid Biopsy in Low-Grade Glioma: A Systematic Review and a Proposal for a Clinical Utility Score.
Zanin L; Sachkova A; Panciani PP; Rohde V; Fontanella MM; Schatlo B
Cell Mol Neurobiol; 2023 Nov; 43(8):3833-3845. PubMed ID: 37704931
[TBL] [Abstract][Full Text] [Related]
5.
Noor H; Zaman A; Teo C; Sughrue ME
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830454
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.
McAleenan A; Kelly C; Spiga F; Kernohan A; Cheng HY; Dawson S; Schmidt L; Robinson T; Brandner S; Faulkner CL; Wragg C; Jefferies S; Howell A; Vale L; Higgins JPT; Kurian KM
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013316. PubMed ID: 33710615
[TBL] [Abstract][Full Text] [Related]
7. Shp1 in Solid Cancers and Their Therapy.
Varone A; Spano D; Corda D
Front Oncol; 2020; 10():935. PubMed ID: 32596156
[TBL] [Abstract][Full Text] [Related]
8. Identification of core differentially methylated genes in glioma.
Xue J; Gao HX; Sang W; Cui WL; Liu M; Zhao Y; Wang MB; Wang Q; Zhang W
Oncol Lett; 2019 Dec; 18(6):6033-6045. PubMed ID: 31788078
[TBL] [Abstract][Full Text] [Related]
9. Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics.
Enninga EA; Nevala WK; Holtan SG; Markovic SN
Front Immunol; 2015; 6():424. PubMed ID: 26379664
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies.
Xia L; Wu B; Fu Z; Feng F; Qiao E; Li Q; Sun C; Ge M
Oncotarget; 2015 Jul; 6(19):17354-65. PubMed ID: 26220714
[TBL] [Abstract][Full Text] [Related]
11. New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.
Dimitrov L; Hong CS; Yang C; Zhuang Z; Heiss JD
Int J Med Sci; 2015; 12(3):201-13. PubMed ID: 25678837
[TBL] [Abstract][Full Text] [Related]
12. Aberrant CpG islands hypermethylation profiles in malignant gliomas.
Kim KR; Kim E; Son EI
Brain Tumor Res Treat; 2014 Apr; 2(1):29-35. PubMed ID: 24926469
[TBL] [Abstract][Full Text] [Related]
13. Incidence and prognostic value of multiple gene promoter methylations in gliomas.
Zhang L; Wang M; Wang W; Mo J
J Neurooncol; 2014 Jan; 116(2):349-56. PubMed ID: 24197988
[TBL] [Abstract][Full Text] [Related]
14. Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas.
Liu BL; Cheng JX; Zhang W; Zhang X; Wang R; Lin H; Huo JL; Cheng H
Neuro Oncol; 2010 Jun; 12(6):540-8. PubMed ID: 20154338
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
16. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
[TBL] [Abstract][Full Text] [Related]
17. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
[TBL] [Abstract][Full Text] [Related]
18. Overview of DNA methylation in adult diffuse gliomas.
Aoki K; Natsume A
Brain Tumor Pathol; 2019 Apr; 36(2):84-91. PubMed ID: 30937703
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
